Posted by Michael Wonder on 09 Jan 2018
GBT receives FDA breakthrough therapy designation for voxelotor for treatment of sickle cell disease
9 January 2018 - Voxelotor is first investigational treatment for sickle cell disease to receive breakthrough therapy designation.
Global Blood Therapeutics today announced that the U.S. FDA has granted breakthrough therapy designation to voxelotor (previously called GBT440) for the treatment of sickle cell disease (SCD).
Voxelotor is being developed as a disease-modifying therapy for SCD and previously received EMA Priority Medicines (PRIME) designation for the treatment of SCD.
